AdAlta

Webinars

Updates

Home

Why Invest

Announcements

Lora

upload.jpg

It was great to discuss the key components of AdAlta’s exciting East-to-West strategy in our latest interview with Stockhead’s Health Kick Podcast hosted by its health and biotech expert Tim Boreham.

The interview gives current and prospective investors in AdAlta the opportunity to hear about the multiple upsides packaged up in our East-to-West strategy, which is bringing Asian cellular immunotherapies to Western markets (a noted ‘hot area’ in the biotech space).

One key upside of the East-to-West strategy is that it will deliver AdAlta a pipeline of clinical stage assets that have already been tested in humans. Another is that growth in this pipeline will be sustainable. It will be delivered by an AdAlta subsidiary, called AdCella, the operations of which will be financed without going cap in hand to AdAlta’s current shareholder base.

The interview explains why AdAlta is targeting drug candidates in the solid cancers segment of the Asian cellular immunotherapies market. It also highlights Asia’s growing role in the drug discovery process, and how AdAlta’s strategy entails a technology transfer process to Western markets, which leverages the advantages Australia enjoys in drug manufacture.

And here’s another recent positive flowing from our now-being-actioned East-to-West strategy - it is largely immune from all the tariff shenanigans currently rattling stock markets.

Listen to the full interview here: https://stockhead.com.au/health/health-kick-podcast-deep-dive-into-adaltas-east-to-west-strategy/

Health Kick Podcast: Deep dive into AdAlta’s East to West strategy